Fulcrum Therapeutics Inc. (FULC): A Brand-New Prospect for Investors – Invest Chronicle

Fulcrum Therapeutics Inc. (FULC): A Brand-New Prospect for Investors

For the readers interested in the stock health of Fulcrum Therapeutics Inc. (FULC). It is currently valued at $4.92. When the transactions were called off in the previous session, Stock hit the highs of $5.15, after setting-off with the price of $4.46. Company’s stock value dipped to $4.46 during the trading on the day. When the trading was stopped its value was $4.49.Recently in News on June 10, 2022, Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan. Fulcrum granted stock options to purchase an aggregate of 112,800 shares of the Company’s common stock to eight new employees. The awards were granted as of June 6, 2022, pursuant to the Company’s 2022 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Fulcrum Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4). You can read further details here

Fulcrum Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $24.79 on 04/05/22, with the lowest value was $3.21 for the same time period, recorded on 06/10/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Fulcrum Therapeutics Inc. (FULC) full year performance was -44.78%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Fulcrum Therapeutics Inc. shares are logging -85.13% during the 52-week period from high price, and 53.27% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.21 and $33.10.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 784496 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Fulcrum Therapeutics Inc. (FULC) recorded performance in the market was -72.19%, having the revenues showcasing -73.56% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 190.90M, as it employees total of 104 workers.

Specialists analysis on Fulcrum Therapeutics Inc. (FULC)

During the last month, 0 analysts gave the Fulcrum Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 11.97, with a change in the price was noted -6.60. In a similar fashion, Fulcrum Therapeutics Inc. posted a movement of -57.29% for the period of last 100 days, recording 749,753 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for FULC is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Trends and Technical analysis: Fulcrum Therapeutics Inc. (FULC)

Raw Stochastic average of Fulcrum Therapeutics Inc. in the period of last 50 days is set at 9.35%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 31.20%. In the last 20 days, the company’s Stochastic %K was 26.45% and its Stochastic %D was recorded 24.62%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -72.19%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -72.06%, alongside a downfall of -44.78% for the period of the last 12 months. The shares increased approximately by 15.22% in the 7-day charts and went up by -42.19% in the period of the last 30 days. Common stock shares were lifted by -73.56% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts